Go Pro
→ A letter from Shannon Stansberry (From Porter & Company) (Ad)tc pixel Free CLDX Stock Alerts

Celldex Therapeutics (CLDX) Financials

Celldex Therapeutics logo
$39.68 0.00 (0.00%)
As of 09/4/2026 04:00 PM Eastern
Compare
Annual Income Statements for Celldex Therapeutics

Annual Income Statements for Celldex Therapeutics

This table shows Celldex Therapeutics' income and expenses over time, based on annual financial data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Income / (Loss) Attributable to Common Shareholders		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Consolidated Net Income / (Loss)		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Net Income / (Loss) Continuing Operations		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Total Pre-Tax Income 		-127 -129 -117 -152 -51 -61 -71 -112 -141 -158 -259
Total Operating Income		 -130 -133 -122 -156 -55 -63 -71 -115 -155 -195 -287
Total Gross Profit		 5.48 6.79 13 9.54 3.57 7.42 4.65 2.36 6.88 7.02 1.55
Total Revenue		 5.48 6.79 13 9.54 3.57 7.42 4.65 2.36 6.88 7.02 1.55
Operating Revenue		 5.48 6.79 13 9.54 3.57 7.42 4.65 2.36 6.88 7.02 1.55
Total Cost of Revenue		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Operating Expenses		 135 140 134 166 59 71 76 118 161 202 289
Selling, General & Admin Expense		 34 36 25 19 15 14 20 27 31 39 44
Research & Development Expense		 100 103 96 66 43 43 53 82 118 164 245
Other Special Charges / (Income)		 - - - - - 0.00 0.00 15 13 0.00 0.00
Total Other Income / (Expense), net		 2.34 4.39 4.21 4.49 4.15 2.41 0.51 2.91 13 37 29
Interest & Investment Income		 2.34 4.39 4.21 4.49 4.15 2.41 0.51 2.91 13 37 29
Basic Earnings per Share		 ($1.31) ($18.99) ($10.86) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45) ($3.90)
Weighted Average Basic Shares Outstanding		 97.05M 6.77M 8.57M 10.44M 14.51M 29.64M 42.87M 46.89M 48.45M 64.40M 66.42M
Diluted Earnings per Share		 ($1.31) ($18.99) ($10.86) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45) ($3.90)
Weighted Average Diluted Shares Outstanding		 97.05M 6.77M 8.57M 10.44M 14.51M 29.64M 42.87M 46.89M 48.45M 64.40M 66.42M
Weighted Average Basic & Diluted Shares Outstanding		 97.05M 6.77M 8.57M 10.44M 14.51M 29.64M 46.74M 47.21M 55.90M 66.38M 66.57M

Quarterly Income Statements for Celldex Therapeutics

This table shows Celldex Therapeutics' income and expenses over time, based on quarterly financial data. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Income / (Loss) Attributable to Common Shareholders		 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79 -74
Consolidated Net Income / (Loss)		 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79 -74
Net Income / (Loss) Continuing Operations		 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79 -74
Total Pre-Tax Income 		-141 -33 -36 -42 -158 -54 -57 -67 -81 -79 -74
Total Operating Income		 -48 -41 -46 -52 -56 -63 -64 -74 -87 -84 -81
Total Gross Profit		 4.13 0.16 2.50 3.19 1.18 0.70 0.73 0.00 0.12 0.02 0.02
Total Revenue		 4.13 0.16 2.50 3.19 1.18 0.70 0.73 0.00 0.12 0.02 0.02
Operating Revenue		 4.13 0.16 2.50 3.19 1.18 0.70 0.73 0.00 0.12 0.02 0.02
Total Cost of Revenue		 - 0.00 0.00 0.00 - 0.00 0.00 0.00 - 0.00 0.00
Total Operating Expenses		 52 41 49 55 57 63 65 74 87 84 81
Selling, General & Admin Expense		 8.83 9.10 9.13 10 10 11 10 11 12 11 13
Research & Development Expense		 30 32 40 45 47 53 54 63 75 73 68
Total Other Income / (Expense), net		 4.32 7.80 10 10 8.94 8.94 7.26 6.57 5.84 5.75 7.12
Interest & Investment Income		 4.32 7.80 10 10 8.94 8.94 7.26 6.57 5.84 5.75 7.12
Basic Earnings per Share		 ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81) ($0.85) ($1.01) ($1.23) ($1.18) ($0.94)
Weighted Average Basic Shares Outstanding		 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M 66.39M 66.42M 66.42M 66.57M 77.84M
Diluted Earnings per Share		 ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81) ($0.85) ($1.01) ($1.23) ($1.18) ($0.94)
Weighted Average Diluted Shares Outstanding		 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M 66.39M 66.42M 66.42M 66.57M 77.84M
Weighted Average Basic & Diluted Shares Outstanding		 55.90M 65.91M 66.29M 66.34M 66.38M 66.39M 66.41M 66.45M 66.57M 78.49M 78.53M

Annual Cash Flow Statements for Celldex Therapeutics

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using annual figures. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Net Change in Cash & Equivalents		 44 -30 -2.17 -16 -13 33 -4.69 -9.71 5.39 -6.46 0.52
Net Cash From Operating Activities		 -99 -113 -100 -75 -46 -40 -61 -104 -107 -158 -211
Net Cash From Continuing Operating Activities		 -99 -113 -100 -75 -46 -40 -61 -104 -107 -158 -211
Net Income / (Loss) Continuing Operations		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Consolidated Net Income / (Loss)		 -127 -129 -93 -151 -51 -60 -71 -112 -141 -158 -259
Depreciation Expense		 3.00 3.10 4.41 3.58 4.86 3.93 3.07 2.90 3.01 3.18 3.38
Amortization Expense		 1.65 3.56 1.19 -0.82 -1.14 -0.73 -3.21 0.84 -6.22 -16 -5.86
Non-Cash Adjustments To Reconcile Net Income		 13 15 0.98 89 5.07 21 12 16 24 34 36
Changes in Operating Assets and Liabilities, net		 11 -6.56 -13 -15 -4.32 -4.52 -2.46 -11 13 -22 14
Net Cash From Investing Activities		 -50 69 46 30 17 -98 -216 90 -106 -290 209
Net Cash From Continuing Investing Activities		 -50 69 46 30 17 -98 -216 90 -106 -290 209
Purchase of Property, Plant & Equipment		 -4.88 -2.75 -1.79 -0.81 -0.73 -1.55 -1.25 -1.83 -1.82 -1.92 -2.71
Purchase of Investments		 -206 -176 -171 -171 -95 -220 -390 -189 -425 -790 -385
Sale and/or Maturity of Investments		 161 243 219 201 113 124 175 281 321 502 596
Other Investing Activities, net		 - - - - - - -0.29 -0.11 -0.08 -0.03 -0.10
Net Cash From Financing Activities		 193 14 51 29 16 171 272 4.08 218 441 2.39
Net Cash From Continuing Financing Activities		 193 14 51 29 16 171 272 4.08 218 441 2.39
Issuance of Common Equity		 193 14 51 29 16 171 272 4.08 218 441 2.39

Quarterly Cash Flow Statements for Celldex Therapeutics

This table details how cash moves in and out of Celldex Therapeutics' business through operations, investing, and financing, using quarterly figures. All values are USD millions unless otherwise specified.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
Net Change in Cash & Equivalents		 14 80 -72 -6.34 -8.04 -11 5.91 13 -7.17 6.86 12
Net Cash From Operating Activities		 -33 -41 -29 -55 -32 -54 -44 -49 -64 -66 -57
Net Cash From Continuing Operating Activities		 -33 -41 -29 -55 -32 -54 -44 -49 -64 -66 -57
Net Income / (Loss) Continuing Operations		 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79 -74
Consolidated Net Income / (Loss)		 -43 -33 -36 -42 -47 -54 -57 -67 -81 -79 -74
Depreciation Expense		 0.76 0.78 0.80 0.79 0.82 0.87 0.87 0.82 0.82 0.85 0.90
Amortization Expense		 -2.18 -3.31 -4.74 -4.33 -3.36 -2.27 -1.69 -1.02 -0.88 -0.63 -1.70
Non-Cash Adjustments To Reconcile Net Income		 7.21 7.21 7.64 9.62 9.78 9.32 9.19 8.81 8.91 8.53 8.41
Changes in Operating Assets and Liabilities, net		 4.98 -13 2.82 -19 7.38 -8.50 4.22 9.80 8.53 4.35 8.48
Net Cash From Investing Activities		 -171 -315 -47 48 24 43 50 61 55 72 -256
Net Cash From Continuing Investing Activities		 -171 -315 -47 48 24 43 50 60 56 72 -256
Purchase of Property, Plant & Equipment		 -0.67 -0.34 -0.27 -0.55 -0.76 -0.27 -0.73 -0.44 -1.28 -1.64 -3.18
Purchase of Investments		 -241 -392 -169 -100 -129 -152 -122 -56 -55 -60 -403
Sale and/or Maturity of Investments		 71 77 122 148 154 195 173 117 112 133 151
Net Cash From Financing Activities		 217 436 3.71 1.24 0.39 0.20 0.06 0.77 1.35 0.33 325
Net Cash From Continuing Financing Activities		 217 436 3.71 1.24 0.39 0.20 0.06 0.77 1.35 0.33 325
Issuance of Common Equity		 217 436 3.71 1.24 0.39 0.20 0.06 0.77 1.35 0.33 325

Annual Balance Sheets for Celldex Therapeutics

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using annual balance sheet data. All values are USD millions unless otherwise specified.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Total Assets		 338 383 316 156 123 236 445 353 466 792 583
Total Current Assets		 295 196 145 99 67 198 411 318 432 747 535
Cash & Equivalents		 72 42 40 24 11 44 39 29 35 28 29
Short-Term Investments		 218 147 99 70 53 151 369 276 389 697 490
Accounts Receivable		 0.97 1.78 1.88 3.16 1.02 1.80 0.17 0.35 2.63 0.70 2.02
Prepaid Expenses		 4.08 4.01 3.45 1.90 1.30 1.62 2.42 12 5.47 21 14
Plant, Property, & Equipment, net		 11 13 10 6.11 4.03 3.82 3.55 3.75 4.06 4.35 5.33
Total Noncurrent Assets		 31 175 160 51 52 34 30 31 30 41 43
Intangible Assets		 21 81 68 49 49 31 27 27 27 27 27
Other Noncurrent Operating Assets		 1.43 2.13 1.93 1.93 3.51 3.49 3.07 4.11 2.68 14 16
Total Liabilities & Shareholders' Equity		 338 383 316 156 123 236 445 353 466 792 583
Total Liabilities		 47 118 79 32 29 26 25 27 36 45 56
Total Current Liabilities		 30 35 28 13 12 14 17 19 31 40 51
Accounts Payable		 1.51 1.74 1.72 1.07 1.17 1.05 1.23 3.34 3.49 3.27 1.18
Accrued Expenses		 24 29 19 7.01 6.50 8.46 12 13 22 34 47
Other Current Liabilities		 4.42 4.83 6.57 4.53 3.97 4.70 3.30 2.44 5.60 2.39 2.78
Total Noncurrent Liabilities		 17 83 52 19 17 12 8.65 7.92 5.33 5.83 4.83
Other Noncurrent Operating Liabilities		 17 83 52 19 17 12 8.65 7.92 5.33 5.83 4.83
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 290 265 236 124 94 209 419 326 429 747 527
Total Preferred & Common Equity		 290 265 236 124 94 209 419 326 429 747 527
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 - 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 290 265 236 124 94 209 419 326 429 747 527
Common Stock		 879 982 1,046 1,084 1,105 1,280 1,561 1,581 1,823 2,299 2,338
Retained Earnings		 -591 -719 -813 -962 -1,013 -1,073 -1,144 -1,256 -1,397 -1,555 -1,814
Accumulated Other Comprehensive Income / (Loss)		 2.31 2.54 2.56 2.58 2.62 2.59 1.89 1.26 3.31 3.31 3.63

Quarterly Balance Sheets for Celldex Therapeutics

This table presents Celldex Therapeutics' assets and liabilities at the end of each period, using quarterly balance sheet data. All values are USD millions unless otherwise specified.

Metric Q1 2023 Q2 2023 Q3 2023 Q1 2024 Q2 2024 Q3 2024 Q1 2025 Q2 2025 Q3 2025 Q1 2026 Q2 2026
Period end date 3/31/2023 6/30/2023 9/30/2023 3/31/2024 6/30/2024 9/30/2024 3/31/2025 6/30/2025 9/30/2025 3/31/2026 6/30/2026
Total Assets		 325 299 280 869 846 823 739 692 648 511 782
Total Current Assets		 290 265 246 835 812 779 694 648 604 459 725
Cash & Equivalents		 54 28 21 115 43 36 17 23 36 36 47
Short-Term Investments		 224 224 214 709 760 720 656 607 547 416 670
Accounts Receivable		 1.31 0.12 0.25 2.67 1.53 0.85 1.06 0.09 0.09 0.23 0.23
Prepaid Expenses		 9.90 12 10 8.81 8.12 22 19 18 21 7.53 7.11
Plant, Property, & Equipment, net		 4.00 3.94 4.16 4.06 3.86 4.23 4.60 4.39 4.83 7.40 9.76
Total Noncurrent Assets		 31 31 30 29 30 40 41 40 39 45 48
Intangible Assets		 27 27 27 27 27 27 27 27 27 27 27
Other Noncurrent Operating Assets		 3.74 3.36 2.97 2.27 2.56 13 14 12 12 17 20
Total Liabilities & Shareholders' Equity		 325 299 280 869 846 823 739 692 648 511 782
Total Liabilities		 22 22 34 30 32 37 36 37 50 55 68
Total Current Liabilities		 15 16 28 26 28 32 32 33 46 51 61
Accounts Payable		 3.37 0.88 3.59 3.23 3.80 1.11 3.41 2.07 4.27 10 15
Accrued Expenses		 9.37 12 18 18 19 28 25 28 40 38 44
Other Current Liabilities		 2.47 2.51 5.78 5.52 5.26 2.78 3.15 2.47 2.48 2.70 2.79
Total Noncurrent Liabilities		 6.56 6.13 5.70 3.94 4.27 5.18 4.47 4.04 3.61 3.56 6.46
Other Noncurrent Operating Liabilities		 6.56 6.13 5.70 3.94 4.27 5.18 4.47 4.04 3.61 3.56 6.46
Commitments & Contingencies		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Equity & Noncontrolling Interests		 303 278 247 839 814 786 703 655 598 456 715
Total Preferred & Common Equity		 303 278 247 839 814 786 703 655 598 456 715
Preferred Stock		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Common Equity		 303 278 247 839 814 786 703 655 598 456 715
Common Stock		 1,586 1,591 1,599 2,267 2,278 2,289 2,308 2,318 2,327 2,346 2,679
Retained Earnings		 -1,285 -1,316 -1,354 -1,430 -1,466 -1,508 -1,609 -1,666 -1,733 -1,893 -1,966
Accumulated Other Comprehensive Income / (Loss)		 2.12 2.07 2.14 2.24 1.78 5.29 3.57 3.34 3.77 2.52 1.30

Annual Metrics And Ratios for Celldex Therapeutics

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric 2015 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025
Period end date 12/31/2015 12/31/2016 12/31/2017 12/31/2018 12/31/2019 12/31/2020 12/31/2021 12/31/2022 12/31/2023 12/31/2024 12/31/2025
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 52.82% 23.83% 87.78% -25.15% -62.54% 107.61% -37.30% -49.32% 192.02% 1.99% -77.99%
EBITDA Growth		 -5.07% -1.10% 8.18% -32.57% 66.61% -17.23% -18.67% -56.19% -41.49% -31.63% -39.58%
EBIT Growth		 -5.81% -2.61% 8.57% -28.73% 64.82% -15.12% -12.45% -61.75% -34.11% -26.23% -47.31%
NOPAT Growth		 -5.81% -2.61% 8.57% -28.73% 64.82% -15.12% -12.45% -61.75% -34.11% -26.23% -47.31%
Net Income Growth		 -7.72% -1.05% 27.62% -62.51% 66.35% -17.50% -17.95% -59.30% -25.91% -11.62% -63.91%
EPS Growth		 0.76% -1.05% 27.62% -62.51% 75.76% 42.45% 18.81% -46.34% -21.67% 16.10% -59.18%
Operating Cash Flow Growth		 2.61% -14.31% 11.59% 24.71% 38.31% 12.95% -50.75% -70.31% -3.43% -47.06% -33.70%
Free Cash Flow Firm Growth		 -0.97% -109.87% 36.87% 59.94% 10.50% 22.26% -55.74% -96.46% -2.00% -65.09% -23.13%
Invested Capital Growth		 -97.97% 34,925.46% 28.14% -69.01% -1.32% -49.62% -24.83% 89.31% -73.78% 289.81% -60.45%
Revenue Q/Q Growth		 6.06% 1.25% 14.17% -15.05% -19.74% 64.15% -42.61% 118.85% 57.69% -29.63% -40.58%
EBITDA Q/Q Growth		 -0.94% -0.43% 6.56% 7.26% -4.44% -20.83% 6.51% -8.12% -15.62% -4.81% -10.97%
EBIT Q/Q Growth		 -1.08% -1.08% 7.13% 7.89% -1.60% -22.87% 5.87% -7.01% -14.65% -4.50% -12.15%
NOPAT Q/Q Growth		 -1.08% -1.08% 7.13% 7.89% -1.60% -22.87% 5.87% -7.01% -14.65% -4.50% -12.15%
Net Income Q/Q Growth		 -0.68% 0.29% 23.43% -3.82% -2.10% -23.70% 2.42% -5.98% -13.50% -2.46% -15.24%
EPS Q/Q Growth		 2.24% 0.29% 23.43% -3.82% -7.67% -64.23% -3.14% -6.19% -10.19% 5.04% -15.38%
Operating Cash Flow Q/Q Growth		 7.89% -6.20% 0.82% 5.16% 8.71% 12.53% -18.05% -7.50% -11.16% 0.04% -17.53%
Free Cash Flow Firm Q/Q Growth		 9.22% -83.37% 31.99% 32.14% 13.07% 22.03% -27.45% -8.35% -10.40% -2.34% -14.23%
Invested Capital Q/Q Growth		 -98.46% 446.48% 23.30% 33.41% 4.15% -50.84% -17.60% -3.16% -50.99% -27.36% -43.25%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -2,279.05% -1,860.60% -909.73% -1,611.27% -1,436.13% -810.92% -1,534.81% -4,730.34% -2,291.97% -2,957.98% -18,760.00%
Operating Margin		 -2,363.89% -1,958.68% -953.68% -1,640.13% -1,540.19% -854.06% -1,531.78% -4,889.01% -2,245.27% -2,778.89% -18,599.81%
EBIT Margin		 -2,363.89% -1,958.68% -953.68% -1,640.13% -1,540.19% -854.06% -1,531.78% -4,889.01% -2,245.27% -2,778.89% -18,599.81%
Profit (Net Income) Margin		 -2,321.11% -1,894.05% -730.06% -1,585.07% -1,423.96% -805.88% -1,516.04% -4,765.59% -2,054.76% -2,248.76% -16,748.03%
Tax Burden Percent		 100.00% 100.00% 79.30% 99.50% 100.00% 98.09% 99.68% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 98.19% 96.70% 96.53% 97.13% 92.45% 96.20% 99.29% 97.48% 91.51% 80.92% 90.04%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -1,674.12% -245.26% -98.58% -172.48% -129.09% -198.97% -381.26% -496.73% -806.56% -1,000.51% -1,327.07%
ROIC Less NNEP Spread (ROIC-NNEP)		 -1,659.24% -230.46% -93.74% -136.77% -113.49% -187.04% -374.41% -487.85% -797.43% -996.80% -1,317.81%
Return on Net Nonoperating Assets (RNNOA)		 1,623.42% 198.99% 61.50% 88.59% 82.43% 159.56% 358.83% 466.60% 769.11% 973.67% 1,286.45%
Return on Equity (ROE)		 -50.70% -46.27% -37.08% -83.89% -46.66% -39.41% -22.43% -30.13% -37.45% -26.84% -40.62%
Cash Return on Invested Capital (CROIC)		 -1,482.10% -444.12% -123.24% -67.10% -127.77% -132.98% -352.90% -558.47% -689.66% -1,118.85% -1,240.43%
Operating Return on Assets (OROA)		 -44.24% -36.87% -34.77% -66.37% -39.49% -35.32% -20.94% -28.90% -37.77% -31.01% -41.79%
Return on Assets (ROA)		 -43.44% -35.66% -26.62% -64.14% -36.51% -33.32% -20.72% -28.17% -34.56% -25.10% -37.63%
Return on Common Equity (ROCE)		 -50.70% -46.27% -37.08% -83.89% -46.66% -39.41% -22.43% -30.13% -37.45% -26.84% -40.62%
Return on Equity Simple (ROE_SIMPLE)		 -43.85% -48.42% -39.36% -121.86% -54.11% -28.55% -16.81% -34.43% -32.95% -21.13% 0.00%
Net Operating Profit after Tax (NOPAT)		 -91 -93 -85 -110 -39 -44 -50 -81 -108 -137 -201
NOPAT Margin		 -1,654.72% -1,371.08% -667.57% -1,148.09% -1,078.13% -597.84% -1,072.24% -3,422.31% -1,571.69% -1,945.22% -13,019.86%
Net Nonoperating Expense Percent (NNEP)		 -14.88% -14.80% -4.84% -35.71% -15.60% -11.93% -6.85% -8.88% -9.13% -3.71% -9.26%
Return On Investment Capital (ROIC_SIMPLE)		 - - - - - - - -24.73% -25.21% -18.28% -38.16%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 617.46% 530.19% 196.21% 202.02% 431.74% 194.88% 440.51% 1,153.80% 449.14% 549.12% 2,837.41%
R&D to Revenue		 1,827.94% 1,513.79% 754.70% 696.68% 1,194.29% 573.39% 1,146.23% 3,489.94% 1,714.53% 2,329.77% 15,862.39%
Operating Expenses to Revenue		 2,463.89% 2,058.68% 1,053.68% 1,740.13% 1,640.19% 954.06% 1,631.78% 4,989.01% 2,345.27% 2,878.89% 18,699.81%
Earnings before Interest and Taxes (EBIT)		 -130 -133 -122 -156 -55 -63 -71 -115 -155 -195 -287
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -125 -126 -116 -154 -51 -60 -71 -111 -158 -208 -290
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 5.33 1.35 1.63 0.28 0.38 3.31 4.30 6.44 4.37 2.24 3.42
Price to Tangible Book Value (P/TBV)		 5.94 3.86 4.96 0.45 0.79 3.88 4.60 7.02 4.66 2.33 3.61
Price to Revenue (P/Rev)		 282.26 52.82 30.31 3.58 10.07 93.45 387.68 890.64 272.34 238.82 1,168.13
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 5,818.87 2.23 2.55 0.00 0.00 33.40 124.25 84.43 260.34 43.79 149.70
Enterprise Value to Revenue (EV/Rev)		 229.36 24.85 19.37 0.00 0.00 67.24 299.90 761.26 210.79 135.50 832.49
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.98 -0.86 -0.66 -0.65 -0.73 -0.85 -0.96 -0.96 -0.96 -0.98 -0.98
Leverage Ratio		 1.17 1.30 1.39 1.31 1.28 1.18 1.08 1.07 1.08 1.07 1.08
Compound Leverage Factor		 1.15 1.25 1.34 1.27 1.18 1.14 1.07 1.04 0.99 0.87 0.97
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 16.79 -1.43 -1.47 -10.59 -11.70 9.42 39.91 42.44 26.60 19.71 14.42
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 9.75 5.55 5.22 7.86 5.73 13.93 24.86 17.07 13.87 18.91 10.49
Quick Ratio		 9.62 5.44 5.09 7.71 5.62 13.81 24.71 16.41 13.69 18.38 10.21
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -80 -168 -106 -43 -38 -30 -46 -91 -93 -153 -188
Operating Cash Flow to CapEx		 -2,028.04% -4,108.91% -5,588.98% -15,973.46% -6,528.13% -2,699.00% -4,984.37% -5,897.21% -5,901.60% -8,221.89% -7,772.48%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.02 0.04 0.04 0.03 0.04 0.01 0.01 0.02 0.01 0.00
Accounts Receivable Turnover		 7.85 4.93 6.96 3.78 1.71 5.27 4.71 9.08 4.63 4.22 1.14
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 0.50 0.55 1.08 1.16 0.70 1.89 1.26 0.65 1.76 1.67 0.32
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 46.52 74.07 52.47 96.47 213.35 69.30 77.46 40.19 78.88 86.52 320.70
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 46.52 74.07 52.47 96.47 213.35 69.30 77.46 40.19 78.88 86.52 320.70
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 0.22 76 97 30 30 15 11 21 5.57 22 8.59
Invested Capital Turnover		 1.01 0.18 0.15 0.15 0.12 0.33 0.36 0.15 0.51 0.51 0.10
Increase / (Decrease) in Invested Capital		 -10 75 21 -67 -0.40 -15 -3.71 10 -16 16 -13
Enterprise Value (EV)		 1,257 169 247 -60 -28 499 1,395 1,794 1,451 951 1,286
Market Capitalization		 1,547 358 386 34 36 693 1,803 2,099 1,874 1,677 1,805
Book Value per Share		 $2.94 $2.62 $1.74 $0.72 $5.83 $5.29 $8.99 $6.93 $9.08 $11.26 $7.93
Tangible Book Value per Share		 $2.64 $0.92 $0.57 $0.44 $2.81 $4.52 $8.41 $6.35 $8.51 $10.85 $7.52
Total Capital		 290 265 236 124 94 209 419 326 429 747 527
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -290 -190 -139 -94 -64 -194 -408 -305 -424 -725 -519
Capital Expenditures (CapEx)		 4.88 2.75 1.79 0.47 0.71 1.50 1.22 1.76 1.82 1.92 2.71
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -25 -29 -22 -7.55 -9.33 -11 -14 -5.87 -23 -18 -35
Debt-free Net Working Capital (DFNWC)		 265 160 117 86 55 184 394 299 401 708 484
Net Working Capital (NWC)		 265 160 117 86 55 184 394 299 401 708 484
Net Nonoperating Expense (NNE)		 37 35 7.96 42 12 15 21 32 33 21 58
Net Nonoperating Obligations (NNO)		 -290 -190 -139 -94 -64 -194 -408 -305 -424 -725 -519
Total Depreciation and Amortization (D&A)		 4.65 6.66 5.60 2.75 3.72 3.20 -0.14 3.74 -3.21 -13 -2.48
Debt-free, Cash-free Net Working Capital to Revenue		 -459.73% -433.69% -175.84% -79.10% -261.07% -145.39% -299.70% -249.00% -334.59% -251.04% -2,258.90%
Debt-free Net Working Capital to Revenue		 4,830.22% 2,362.89% 918.31% 906.66% 1,540.86% 2,475.56% 8,477.98% 12,689.14% 5,819.67% 10,080.60% 31,305.70%
Net Working Capital to Revenue		 4,830.22% 2,362.89% 918.31% 906.66% 1,540.86% 2,475.56% 8,477.98% 12,689.14% 5,819.67% 10,080.60% 31,305.70%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($19.65) ($19.05) ($10.80) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45) ($3.90)
Adjusted Weighted Average Basic Shares Outstanding		 6.58M 8.21M 9.40M 12.44M 17.57M 39.61M 42.87M 46.89M 48.45M 64.40M 66.42M
Adjusted Diluted Earnings per Share		 ($19.65) ($19.05) ($10.80) ($14.48) ($3.51) ($2.02) ($1.64) ($2.40) ($2.92) ($2.45) ($3.90)
Adjusted Weighted Average Diluted Shares Outstanding		 6.58M 8.21M 9.40M 12.44M 17.57M 39.61M 42.87M 46.89M 48.45M 64.40M 66.42M
Adjusted Basic & Diluted Earnings per Share		 ($19.65) ($19.05) ($10.80) ($14.48) ($3.51) ($2.02) $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 6.47M 6.77M 8.57M 10.44M 14.51M 29.64M 46.74M 47.21M 55.90M 66.38M 66.57M
Normalized Net Operating Profit after Tax (NOPAT)		 -91 -93 -76 -33 -37 -32 -47 -70 -99 -137 -201
Normalized NOPAT Margin		 -1,654.72% -1,371.08% -596.16% -343.34% -1,042.87% -427.98% -1,019.57% -2,976.83% -1,444.56% -1,945.22% -13,019.86%
Pre Tax Income Margin		 -2,321.11% -1,894.05% -920.61% -1,593.09% -1,423.96% -821.61% -1,520.92% -4,765.59% -2,054.76% -2,248.76% -16,748.03%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Quarterly Metrics And Ratios for Celldex Therapeutics

This table displays calculated financial ratios and metrics derived from Celldex Therapeutics' official financial filings.

Metric Q4 2023 Q1 2024 Q2 2024 Q3 2024 Q4 2024 Q1 2025 Q2 2025 Q3 2025 Q4 2025 Q1 2026 Q2 2026
Period end date 12/31/2023 3/31/2024 6/30/2024 9/30/2024 12/31/2024 3/31/2025 6/30/2025 9/30/2025 12/31/2025 3/31/2026 6/30/2026
DEI Shares Outstanding		 - - - - - - - - - 66,566,346.00 78,492,072.00
DEI Adjusted Shares Outstanding		 - - - - - - - - - 66,566,346.00 78,492,072.00
DEI Earnings Per Adjusted Shares Outstanding		 - - - - - - - - - -1.18 -0.94
Growth Metrics		 - - - - - - - - - - -
Revenue Growth		 156.11% -83.87% 832.09% 110.35% -71.56% 345.51% -70.78% -100.00% -89.79% -97.84% -96.99%
EBITDA Growth		 -76.85% -30.74% -49.54% -32.24% -19.42% -48.66% -28.67% -32.58% -48.91% -31.29% -25.90%
EBIT Growth		 -70.80% -25.06% -39.49% -26.40% -17.64% -54.50% -37.87% -41.23% -55.56% -34.58% -26.26%
NOPAT Growth		 -70.80% -25.06% -39.49% -26.40% -17.64% -54.50% -37.87% -41.23% -55.56% -34.58% -26.26%
Net Income Growth		 -63.50% -11.74% -17.51% -10.09% -8.74% -63.97% -57.92% -59.17% -72.68% -46.27% -29.86%
EPS Growth		 -47.37% 9.68% 16.92% 20.99% 15.48% -44.64% -57.41% -57.81% -73.24% -45.68% -10.59%
Operating Cash Flow Growth		 -49.49% -42.25% -7.84% -191.35% 0.18% -33.80% -50.05% 12.12% -96.88% -20.63% -30.46%
Free Cash Flow Firm Growth		 40.23% 36.03% 52.46% -200.81% -213.53% -212.32% -208.75% 33.18% 13.53% 41.91% 51.49%
Invested Capital Growth		 -73.78% -39.36% -54.34% 163.03% 289.81% 101.06% 121.03% -49.37% -60.45% -83.94% -112.06%
Revenue Q/Q Growth		 172.31% -96.22% 1,501.28% 27.74% -63.18% -40.85% 5.04% -100.00% 0.00% -87.50% 46.67%
EBITDA Q/Q Growth		 -16.50% 12.03% -16.49% -10.77% -5.21% -9.51% -0.83% -14.13% -18.17% 3.45% 3.32%
EBIT Q/Q Growth		 -15.49% 14.74% -14.06% -12.54% -7.48% -11.98% -1.78% -15.28% -18.39% 3.12% 4.51%
NOPAT Q/Q Growth		 -15.49% 14.74% -14.06% -12.54% -7.48% -11.98% -1.78% -15.28% -18.39% 3.12% 4.51%
Net Income Q/Q Growth		 -13.19% 24.24% -9.25% -17.52% -11.80% -14.24% -5.21% -18.45% -21.29% 3.24% 6.59%
EPS Q/Q Growth		 -3.70% 33.33% 3.57% -18.52% -10.94% -14.08% -4.94% -18.82% -21.78% 4.07% 20.34%
Operating Cash Flow Q/Q Growth		 -71.29% -24.91% 27.83% -88.69% 41.31% -67.42% 19.07% -10.51% -31.49% -2.58% 12.47%
Free Cash Flow Firm Q/Q Growth		 3.46% -6.68% -0.45% -190.77% -0.63% -6.27% 0.70% 37.07% -30.22% 28.60% 17.08%
Invested Capital Q/Q Growth		 -50.99% 164.97% -23.19% 163.67% -27.36% 36.67% -15.56% -39.61% -43.25% -44.51% -163.40%
Profitability Metrics		 - - - - - - - - - - -
Gross Margin		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 0.00% 100.00% 100.00% 100.00%
EBITDA Margin		 -1,187.29% -27,657.69% -2,012.01% -1,744.69% -4,984.77% -9,228.63% -8,859.18% 0.00% -72,683.33% -561,406.67% -370,086.36%
Operating Margin		 -1,152.92% -26,030.77% -1,854.16% -1,633.53% -4,768.26% -9,027.19% -8,747.53% 0.00% -72,628.33% -562,900.00% -366,468.18%
EBIT Margin		 -1,152.92% -26,030.77% -1,854.16% -1,633.53% -4,768.26% -9,027.19% -8,747.53% 0.00% -72,628.33% -562,900.00% -366,468.18%
Profit (Net Income) Margin		 -1,048.32% -21,030.77% -1,434.83% -1,319.99% -4,007.83% -7,740.43% -7,753.42% 0.00% -67,764.17% -524,566.67% -334,104.55%
Tax Burden Percent		 30.62% 100.00% 0.00% 0.00% 29.83% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Interest Burden Percent		 296.95% 80.79% 0.00% 0.00% 281.76% 85.75% 88.64% 91.07% 93.30% 93.19% 91.17%
Effective Tax Rate		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Return on Invested Capital (ROIC)		 -414.16% -5,656.50% -595.62% -552.73% -1,716.76% -2,148.84% -1,947.76% 0.00% -5,181.92% -19,782.69% -3,653.71%
ROIC Less NNEP Spread (ROIC-NNEP)		 -411.42% -5,655.71% -594.97% -551.60% -1,715.39% -2,147.53% -1,946.10% 0.00% -5,178.65% -19,779.21% -3,651.18%
Return on Net Nonoperating Assets (RNNOA)		 396.81% 5,461.86% 575.24% 529.55% 1,675.58% 2,085.59% 1,897.86% 0.00% 5,055.44% 19,191.26% 3,592.42%
Return on Equity (ROE)		 -17.35% -194.65% -20.38% -23.18% -41.18% -63.25% -49.90% 0.00% -126.48% -591.43% -61.29%
Cash Return on Invested Capital (CROIC)		 -689.66% -533.18% -605.58% -722.99% -1,118.85% -751.15% -978.01% -730.82% -1,240.43% -1,111.05% 0.00%
Operating Return on Assets (OROA)		 -19.39% -264.90% -26.89% -29.54% -53.22% -84.85% -65.87% 0.00% -163.18% -778.60% -78.03%
Return on Assets (ROA)		 -17.63% -214.01% -20.81% -23.87% -44.73% -72.76% -58.39% 0.00% -152.25% -725.58% -71.14%
Return on Common Equity (ROCE)		 -17.35% -194.65% -20.38% -23.18% -41.18% -63.25% -49.90% 0.00% -126.48% -591.43% -61.29%
Return on Equity Simple (ROE_SIMPLE)		 0.00% -17.28% -18.46% -19.61% 0.00% -25.44% 0.00% 0.00% 0.00% 0.00% 0.00%
Net Operating Profit after Tax (NOPAT)		 -33 -28 -32 -36 -39 -44 -45 -52 -61 -59 -56
NOPAT Margin		 -807.04% -18,221.54% -1,297.91% -1,143.47% -3,337.78% -6,319.04% -6,123.27% 0.00% -50,839.83% -394,030.00% -256,527.73%
Net Nonoperating Expense Percent (NNEP)		 -2.74% -0.80% -0.65% -1.14% -1.37% -1.32% -1.66% -2.32% -3.27% -3.48% -2.53%
Return On Investment Capital (ROIC_SIMPLE)		 -7.77% -3.39% - - -5.25% -6.25% -6.82% -8.61% -11.57% -12.96% -7.90%
Cost of Revenue to Revenue		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
SG&A Expenses to Revenue		 213.80% 5,835.26% 365.41% 315.07% 873.45% 1,556.83% 1,423.42% 0.00% 9,950.83% 76,326.67% 59,559.09%
R&D to Revenue		 736.53% 20,295.51% 1,588.75% 1,418.46% 3,994.81% 7,570.36% 7,424.11% 0.00% 62,777.50% 486,673.33% 307,009.09%
Operating Expenses to Revenue		 1,252.92% 26,130.77% 1,954.16% 1,733.53% 4,868.26% 9,127.19% 8,847.53% 0.00% 72,728.33% 563,000.00% 366,568.18%
Earnings before Interest and Taxes (EBIT)		 -48 -41 -46 -52 -56 -63 -64 -74 -87 -84 -81
Earnings before Interest, Taxes, Depreciation and Amortization (EBITDA)		 -49 -43 -50 -56 -59 -64 -65 -74 -87 -84 -81
Valuation Ratios		 - - - - - - - - - - -
Price to Book Value (P/BV)		 4.37 2.37 3.00 2.87 2.24 1.71 2.06 2.87 3.42 4.63 4.09
Price to Tangible Book Value (P/TBV)		 4.66 2.44 3.10 2.97 2.33 1.78 2.15 3.01 3.61 4.92 4.25
Price to Revenue (P/Rev)		 272.34 326.69 293.83 225.85 238.82 159.39 233.31 660.75 1,168.13 2,441.02 18,603.12
Price to Earnings (P/E)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Dividend Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Earnings Yield		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Enterprise Value to Invested Capital (EV/IC)		 260.34 78.54 144.33 50.06 43.79 17.90 28.75 74.95 149.70 348.16 0.00
Enterprise Value to Revenue (EV/Rev)		 210.79 191.01 197.19 150.07 135.50 70.32 124.47 436.43 832.49 1,919.11 14,032.50
Enterprise Value to EBITDA (EV/EBITDA)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to EBIT (EV/EBIT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to NOPAT (EV/NOPAT)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Operating Cash Flow (EV/OCF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Enterprise Value to Free Cash Flow (EV/FCFF)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Leverage & Solvency		 - - - - - - - - - - -
Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to Equity		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Financial Leverage		 -0.96 -0.97 -0.97 -0.96 -0.98 -0.97 -0.98 -0.97 -0.98 -0.97 -0.98
Leverage Ratio		 1.08 1.05 1.05 1.07 1.07 1.04 1.05 1.06 1.08 1.08 1.08
Compound Leverage Factor		 3.22 0.84 0.00 0.00 3.01 0.89 0.93 0.97 1.01 1.01 0.98
Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Short-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Long-Term Debt to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Preferred Equity to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Noncontrolling Interests to Total Capital		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Common Equity to Total Capital		 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00% 100.00%
Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to EBITDA		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Long-Term Debt to NOPAT		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Altman Z-Score		 27.36 38.03 44.36 34.60 20.29 17.57 19.31 17.50 15.55 18.25 23.01
Noncontrolling Interest Sharing Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Liquidity Ratios		 - - - - - - - - - - -
Current Ratio		 13.87 31.77 29.36 24.27 18.91 21.67 19.67 13.01 10.49 8.92 11.82
Quick Ratio		 13.69 31.44 29.06 23.58 18.38 21.06 19.13 12.55 10.21 8.78 11.71
Cash Flow Metrics		 - - - - - - - - - - -
Free Cash Flow to Firm (FCFF)		 -18 -19 -19 -55 -55 -59 -58 -37 -48 -34 -28
Operating Cash Flow to CapEx		 -4,884.83% -11,813.37% -10,703.28% -10,153.58% -4,295.77% -20,517.74% -6,044.64% -11,051.82% -4,991.41% -4,001.71% -1,805.91%
Free Cash Flow to Firm to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Operating Cash Flow Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Efficiency Ratios		 - - - - - - - - - - -
Asset Turnover		 0.02 0.01 0.01 0.02 0.01 0.01 0.01 0.00 0.00 0.00 0.00
Accounts Receivable Turnover		 4.63 3.05 10.05 18.07 4.22 4.05 7.13 5.52 1.14 1.34 0.98
Inventory Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Fixed Asset Turnover		 1.76 1.51 2.13 2.38 1.67 1.75 1.40 0.57 0.32 0.14 0.02
Accounts Payable Turnover		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Sales Outstanding (DSO)		 78.88 119.77 36.32 20.20 86.52 90.18 51.18 66.12 320.70 273.01 371.97
Days Inventory Outstanding (DIO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Days Payable Outstanding (DPO)		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Cash Conversion Cycle (CCC)		 78.88 119.77 36.32 20.20 86.52 90.18 51.18 66.12 320.70 273.01 371.97
Capital & Investment Metrics		 - - - - - - - - - - -
Invested Capital		 5.57 15 11 30 22 30 25 15 8.59 4.77 -3.02
Invested Capital Turnover		 0.51 0.31 0.46 0.48 0.51 0.34 0.32 0.12 0.10 0.05 0.01
Increase / (Decrease) in Invested Capital		 -16 -9.59 -13 19 16 15 14 -15 -13 -25 -28
Enterprise Value (EV)		 1,451 1,160 1,637 1,497 951 532 721 1,135 1,286 1,660 2,203
Market Capitalization		 1,874 1,984 2,439 2,253 1,677 1,205 1,351 1,718 1,805 2,111 2,921
Book Value per Share		 $9.08 $14.24 $12.34 $11.86 $11.26 $10.59 $9.87 $9.01 $7.93 $6.85 $9.10
Tangible Book Value per Share		 $8.51 $13.78 $11.93 $11.45 $10.85 $10.18 $9.46 $8.60 $7.52 $6.45 $8.76
Total Capital		 429 839 814 786 747 703 655 598 527 456 715
Total Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Total Long-Term Debt		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Net Debt		 -424 -824 -802 -756 -725 -673 -630 -583 -519 -451 -718
Capital Expenditures (CapEx)		 0.67 0.34 0.27 0.55 0.76 0.27 0.73 0.44 1.28 1.64 3.18
Debt-free, Cash-free Net Working Capital (DFCFNWC)		 -23 -15 -18 -9.25 -18 -12 -15 -25 -35 -44 -54
Debt-free Net Working Capital (DFNWC)		 401 809 784 747 708 662 615 558 484 408 664
Net Working Capital (NWC)		 401 809 784 747 708 662 615 558 484 408 664
Net Nonoperating Expense (NNE)		 9.97 4.38 3.42 5.63 7.87 9.88 12 16 20 20 17
Net Nonoperating Obligations (NNO)		 -424 -824 -802 -756 -725 -673 -630 -583 -519 -451 -718
Total Depreciation and Amortization (D&A)		 -1.42 -2.54 -3.94 -3.55 -2.54 -1.40 -0.82 -0.19 -0.07 0.22 -0.80
Debt-free, Cash-free Net Working Capital to Revenue		 -334.59% -243.96% -216.82% -92.72% -251.04% -152.82% -257.23% -974.96% -2,258.90% -5,052.95% -34,382.80%
Debt-free Net Working Capital to Revenue		 5,819.67% 13,324.00% 9,447.33% 7,485.46% 10,080.60% 8,754.32% 10,627.54% 21,456.69% 31,305.70% 47,138.73% 422,678.98%
Net Working Capital to Revenue		 5,819.67% 13,324.00% 9,447.33% 7,485.46% 10,080.60% 8,754.32% 10,627.54% 21,456.69% 31,305.70% 47,138.73% 422,678.98%
Earnings Adjustments		 - - - - - - - - - - -
Adjusted Basic Earnings per Share		 ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81) ($0.85) ($1.01) ($1.23) ($1.18) ($0.94)
Adjusted Weighted Average Basic Shares Outstanding		 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M 66.39M 66.42M 66.42M 66.57M 77.84M
Adjusted Diluted Earnings per Share		 ($0.84) ($0.56) ($0.54) ($0.64) ($0.71) ($0.81) ($0.85) ($1.01) ($1.23) ($1.18) ($0.94)
Adjusted Weighted Average Diluted Shares Outstanding		 48.45M 58.87M 66.02M 66.29M 64.40M 66.38M 66.39M 66.42M 66.42M 66.57M 77.84M
Adjusted Basic & Diluted Earnings per Share		 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00 $0.00
Adjusted Weighted Average Basic & Diluted Shares Outstanding		 55.90M 65.91M 66.29M 66.34M 66.38M 66.39M 66.41M 66.45M 66.57M 78.49M 78.53M
Normalized Net Operating Profit after Tax (NOPAT)		 -33 -28 -32 -36 -39 -44 -45 -52 -61 -59 -56
Normalized NOPAT Margin		 -807.04% -18,221.54% -1,297.91% -1,143.47% -3,337.78% -6,319.04% -6,123.27% 0.00% -50,839.83% -394,030.00% -256,527.73%
Pre Tax Income Margin		 -3,423.60% -21,030.77% 0.00% 0.00% -13,435.15% -7,740.43% -7,753.42% 0.00% -67,764.17% -524,566.67% -334,104.55%
Debt Service Ratios		 - - - - - - - - - - -
EBIT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
EBIT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
NOPAT Less CapEx to Interest Expense		 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Payout Ratios		 - - - - - - - - - - -
Dividend Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%
Augmented Payout Ratio		 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00% 0.00%

Financials Breakdown Chart

Key Financial Trends

Celldex Therapeutics (NASDAQ: CLDX) remains a development-stage biotechnology company with substantial liquidity but persistent operating losses. The latest quarter showed only $22,000 of revenue, compared with $730,000 in Q2 2025 and $2.5 million in Q2 2024. Revenue has remained very small and volatile, providing little support for the company’s research spending.

Net losses have generally widened over the period. Celldex reported a $26.8 million loss in Q4 2022, a $56.6 million loss in Q2 2025 and a $73.5 million loss in Q2 2026. The latest loss equaled a basic loss of $0.94 per share, an improvement from the $1.18 loss per share reported in Q1 2026 but worse than the $0.85 loss per share recorded in Q2 2025.

Research and development spending is the primary driver of the deficit. R&D expense increased from $22.9 million in Q4 2022 to $67.5 million in Q2 2026. Selling, general and administrative expense also rose over that period, from $6.6 million to $13.1 million. The increase reflects heavier investment in Celldex’s pipeline, but it also means the company’s path to profitability depends heavily on successful clinical development and future commercialization.

Cash flow shows the same funding pressure. Operating cash outflow was $57.4 million in Q2 2026, compared with $44.0 million in Q2 2025, $29.3 million in Q2 2024 and $22.2 million in Q2 2023. Celldex has reported negative operating cash flow in every period supplied, indicating that the business is not yet self-funding.

The balance sheet, however, strengthened materially in the latest quarter. Cash and short-term investments totaled approximately $714.7 million at June 30, 2026, up from $451.5 million at March 31, 2026. Total assets rose to $782.3 million from $511.3 million. The increase was driven primarily by a $324.7 million common-stock issuance and investment activity, rather than operating profitability.

  • Large liquidity cushion: Cash and short-term investments of approximately $714.7 million provide meaningful funding for clinical programs and corporate operations.
  • Low financial leverage: Total liabilities were only $67.8 million against $714.6 million of equity, and the company reported no preferred stock or material debt in the supplied statements.
  • Strong short-term balance-sheet coverage: Current assets of $724.9 million compared with current liabilities of $61.3 million imply substantial coverage of near-term obligations.
  • Investment income helps offset spending: Interest and investment income reached $7.1 million in Q2 2026, up from $5.8 million in Q4 2025 and $4.3 million in Q4 2023.
  • Recent operating loss improvement: The Q2 2026 net loss narrowed from $78.7 million in Q1 2026 to $73.5 million, while R&D expense declined from $73.0 million to $67.5 million.
  • Estimated cash runway remains substantial but uncertain: Comparing the $714.7 million liquidity balance with the latest $57.4 million quarterly operating cash burn suggests several years of funding, although burn rates can change significantly as clinical programs advance.
  • Investment balances fluctuate: Celldex has repeatedly moved large amounts between purchases and maturities of investments, so changes in cash and short-term investments do not necessarily represent improvements in operating performance.
  • Persistent operating losses: Net losses have expanded from $26.8 million in Q4 2022 to $73.5 million in Q2 2026, with no evidence in the supplied data of a near-term break-even trend.
  • Operating cash burn is accelerating: Q2 2026 operating cash outflow was approximately 30% higher than in Q2 2025 and more than double the Q2 2022 outflow of $22.2 million.
  • Shareholder dilution is significant: Basic weighted-average shares increased from 46.9 million in Q4 2022 to 77.8 million in Q2 2026. The latest $324.7 million equity raise improved liquidity but also increased the share base and reduced each existing shareholder’s ownership percentage.

Investor takeaway: CLDX’s financial position is supported by a large investment portfolio, minimal liabilities and recent access to equity financing. Nevertheless, the company remains dependent on outside capital because revenue is negligible and operating cash flow is consistently negative. For retail investors, clinical results, pipeline progress and the pace of future cash burn are likely to matter more than current revenue or earnings metrics.

09/07/26 05:32 AM ETAI Generated. May Contain Errors.

Celldex Therapeutics Financials - Frequently Asked Questions

According to the most recent income statement we have on file, Celldex Therapeutics' financial year ends in December. Their financial year 2025 ended on December 31, 2025.

Celldex Therapeutics' net income appears to be on an upward trend, with a most recent value of -$258.76 million in 2025, rising from -$127.20 million in 2015. The previous period was -$157.86 million in 2024. View Celldex Therapeutics' forecast to see where analysts expect Celldex Therapeutics to go next.

Celldex Therapeutics' total operating income in 2025 was -$287.37 million, based on the following breakdown:
  • Total Gross Profit: $1.55 million
  • Total Operating Expenses: $288.91 million

Over the last 10 years, Celldex Therapeutics' total revenue changed from $5.48 million in 2015 to $1.55 million in 2025, a change of -71.8%.

Celldex Therapeutics' total liabilities were at $55.82 million at the end of 2025, a 23.1% increase from 2024, and a 17.6% increase since 2015.

In the past 10 years, Celldex Therapeutics' cash and equivalents has ranged from $11.23 million in 2019 to $72.11 million in 2015, and is currently $28.87 million as of their latest financial filing in 2025.

Over the last 10 years, Celldex Therapeutics' book value per share changed from 2.94 in 2015 to 7.93 in 2025, a change of 169.8%.


Related Companies

Financial statements for NASDAQ:CLDX last updated on 8/6/2026 by MarketBeat.com Staff. New filings and market data are monitored continuously.
From Our Partners
ALERT: Drop these 5 stocks before the market opens tomorrow!
The Wall Street Journal is already raising the alarm about a potential market crash, and Weiss Ratings researc...
Weiss Ratings | Sponsoredtc pixel
Small Colorado Company (Backed by Sam Altman) Could Save U.S. Power Grid
A small Colorado company has secured rights to technology that could prevent the U.S. public power grid from c...
Altimetry | Sponsoredtc pixel
The end may be near for these iconic stocks
Marc Chaikin, founder of Chaikin Analytics, says two forces - AI disruption and fracturing global trade - are ...
Chaikin Analytics | Sponsoredtc pixel
Louis Navellier: My #1 AI stock for 2026 (name & ticker inside)
Louis Navellier's Stock Grader system helped him flag Nvidia before its 82,000% run and has identified the top...
InvestorPlace | Sponsoredtc pixel
Ready to give options a try? Your first trade (Ticker included) -INSIDE
Tired of trying tactic after tactic when it comes to options trades... only to be met with market noise and st...
Base Camp Trading | Sponsoredtc pixel
The $15 Gold Fund That Pays Up to $1,152/Month
Gold is hitting record highs, but most investors are leaving income on the table. A $15 fund is quietly paying...
Investors Alley | Sponsoredtc pixel
Iran War Shock: What I Was Told In That Private Meeting
You’re Being LIED To About The Iran War Forget EVERYTHING you’ve heard about the Iran war. Especially th...
Banyan Hill Publishing | Sponsoredtc pixel
My top 3 AI picks for the next decade
Alexander Green bought Apple in 1996, recommended Nvidia at a split-adjusted 66 cents in 2004, and picked up A...
The Oxford Club | Sponsoredtc pixel